^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CS-1 inhibitor

    Related drugs:
    22d
    SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma. (PubMed, Cancers (Basel))
    The target has a proven clinical success with Elotuzumab (anti-SLAMF7 antibody); it works by activating immune cells to kill myeloma cells, and limited expression on normal tissues, with, potentially, few side effects...However, 'fratricide death', a phenomenon where the engineered CAR-T cells attack and kill each other, is a critical issue that requires safe engineering solutions. In this work, we will provide an overview on the field with a specific focus on SLAMF7 as an emerging CAR-T cell target in MM.
    Review • Journal • IO biomarker
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Empliciti (elotuzumab)
    2ms
    Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HLA-A*02 positive
    |
    Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410
    2ms
    PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • PVX-410
    3ms
    Elo-KRd: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, University of Chicago | Trial completion date: Mar 2029 --> Mar 2027
    Trial completion date
    |
    lenalidomide • carfilzomib • Empliciti (elotuzumab)
    3ms
    A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Hiltonol (poly-ICLC) • PVX-410 • citarinostat (ACY-241)
    3ms
    A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    bortezomib • pomalidomide • Empliciti (elotuzumab)
    4ms
    Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma. (PubMed, Front Immunol)
    These results suggest that the CARtein platform is a promising, versatile, and highly specific approach for the modular design and engineering of CARs, enabling multi-antigen targeting while maintaining structural and functional integrity. This modular strategy addresses key limitations of conventional CAR T-cell therapy and may improve both the safety and effectiveness of future MM treatments.
    Journal
    |
    SLAMF7 (SLAM Family Member 7)
    4ms
    CA204-219: A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan (clinicaltrials.gov)
    P=N/A, N=7, Completed, Bristol-Myers Squibb | Recruiting --> Completed | N=27 --> 7 | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: Jun 2025 --> Mar 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    lenalidomide • pomalidomide • Empliciti (elotuzumab)
    6ms
    Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies. (PubMed, Br J Haematol)
    Interestingly, isatuximab showed an opposite pattern, with complete loss of CD38 detection by JK36, while retaining dim positivity by HB-7. This combination of markers proved highly effective in identifying abnormal PCs after CD38-directed therapies, supporting a need for redundancy of gating markers in FC panels.
    Journal • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SDC1 (Syndecan 1) • SLAMF7 (SLAM Family Member 7)
    |
    Darzalex (daratumumab) • Sarclisa (isatuximab-irfc)
    6ms
    Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series. (PubMed, Hematology)
    None of the patients died during the median follow-up period of 39 months (range, 3-66 months). Daratumumab- and elotuzumab-based regimens may be treatment options for refractory POEMS syndrome.
    Retrospective data • Journal
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Darzalex (daratumumab) • Empliciti (elotuzumab)
    6ms
    SWOG-1211: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=142, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Mar 2025 --> Dec 2025
    Trial completion date
    |
    SKY92 Test
    |
    lenalidomide • bortezomib • Empliciti (elotuzumab) • dexamethasone injection
    6ms
    CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab)